We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Skip to main content

Advertisement

SpringerLink
Log in

Chronic myeloproliferative neoplasms

Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy

  • Letter
  • Published:
Leukemia Submit manuscript

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Clonal evolution of chronic neutrophilic leukemia in patients on ruxolitinib.

References

  1. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368:1781–90.

    Article  CAS  Google Scholar 

  2. Dao KT, Tyner JW, Gotlib J. Recent progress in chronic neutrophilic leukemia and atypical chronic myeloid leukemia. Curr Hematologic Malig Rep. 2017;12:432–41.

    Article  Google Scholar 

  3. Miller CA, McMichael J, Dang HX, Maher CA, Ding L, Ley TJ, et al. Visualizing tumor evolution with the fishplot package for R. BMC Genom. 2016;17:880.

    Article  Google Scholar 

  4. Aarts LHJ, Roovers O, Ward AC, Touw IP. Receptor activation and 2 distinct COOH-terminal motifs control G-CSF receptor distribution and internalization kinetics. Blood. 2004;103:571.

    Article  CAS  Google Scholar 

  5. Lasho TL, Mims A, Elliott MA, Finke C, Pardanani A, Tefferi A. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. Leukemia. 2014;28:1363.

    Article  CAS  Google Scholar 

  6. Nooruddin Z, Miltgen N, Wei Q, Schowinsky J, Pan Z, Tobin J, et al. Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. Haematologica. 2017;102:e207–9.

    Article  Google Scholar 

  7. Gunawan AS, McLornan DP, Wilkins B, Waghorn K, Hoade Y, Cross NCP, et al. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. Haematologica. 2017;102:e238–40.

    Article  Google Scholar 

  8. Dong F, Qiu Y, Yi T, Touw IP, Larner AC. The carboxyl terminus of the granulocyte colony-stimulating factor receptor, truncated in patients with severe congenital neutropenia/acute myeloid leukemia, is required for SH2-containing phosphatase-1 suppression of Stat activation. J Immunol. 2001;167:6447–52.

    Article  CAS  Google Scholar 

  9. Hirsch P, Zhang Y, Tang R, Joulin V, Boutroux H, Pronier E, et al. Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia. Nat Commun. 2016;7:12475.

    Article  CAS  Google Scholar 

  10. Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, Ramakrishnan A, et al. SRSF2 Mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27:617–30.

    Article  CAS  Google Scholar 

  11. Couronne L, Scourzic L, Pilati C, Della Valle V, Duffourd Y, Solary E, et al. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica. 2013;98:1748–52.

    Article  CAS  Google Scholar 

  12. Skokowa J, Steinemann D, Katsman-Kuipers JE, Zeidler C, Klimenkova O, Klimiankou M, et al. Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood. 2014;123:2229–37.

    Article  CAS  Google Scholar 

  13. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367–76.

    Article  CAS  Google Scholar 

  14. Lv K, Jiang J, Donaghy R, Riling CR, Cheng Y, Chandra V, et al. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies. Genes Dev. 2017;31:1007–23.

    Article  CAS  Google Scholar 

  15. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113:6182–92.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by Incyte, Inc. KHD served on advisory board meetings and received compensation from Incyte. JWT received grants from the National Cancer Institute (1U01CA217862, 1U54CA224019, and 1R01CA183947), the V Foundation for Cancer Research, and the Gabrielle’s Angel Foundation for Cancer Research. JWT has received research support from Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Gilead, Incyte, Janssen, Seattle Genetics, Syros, and Takeda; JWT is a co-founder of Vivid Biosciences.

Author information

Authors and Affiliations

  1. School of Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, mailcode KR-HEM, Portland, OR, 97239, USA

    Ryan C. Stoner & Julia E. Maxson

  2. Department of Pathology, Oregon Health & Science University, Portland, OR, 97239, USA

    Richard D. Press

  3. Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97239, USA

    Richard D. Press, Julia E. Maxson, Jeffrey W. Tyner & Kim-Hien T. Dao

  4. Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, 97239, USA

    Jeffrey W. Tyner & Kim-Hien T. Dao

  5. Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, 97239, USA

    Jeffrey W. Tyner

Authors
  1. Ryan C. Stoner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard D. Press
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julia E. Maxson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeffrey W. Tyner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kim-Hien T. Dao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kim-Hien T. Dao.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stoner, R.C., Press, R.D., Maxson, J.E. et al. Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy. Leukemia 34, 1684–1688 (2020). https://doi.org/10.1038/s41375-019-0688-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-019-0688-1

  • Springer Nature Limited

Search

Navigation